Overview

CRBP

Nasdaq

Corbus Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery

Press Release Webcast

Corbus Closing Bell Video

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

Sep 20, 2018

Read Press Release

Q2 2018

Quarterly Results

Jun 30, 2018

PDF HTML

Earnings Release

PDF HTML

10-Q

HTML

Financials

ZIP XLS HTML

XBRL

Symbol

Nasdaq: CRBP

Price

Change

MKT Cap

Volume

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2^nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.

Yuval Cohen, Ph.D.

Chief Executive Officer, Director

Yuval Cohen, Ph.D., joined Corbus in July 2013 as Chief Executive Officer. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq CLTX) from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus View Full Bio

Mark A. Tepper, Ph.D.

President & Chief Scientific Officer

Mark A. Tepper, Ph.D., co-founded the Company in 2009. He has more than twenty years of leadership experience in pharmaceutical R&D and his past roles include leadership positions at Bristol Myers Squibb, Serono, CytRx, RXi View Full Bio

Barbara White, M.D.

Chief Medical Officer

Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and View Full Bio

Sean Moran, CPA, MBA

Chief Financial Officer

Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery and medical device companies. Mr. Moran has successfully managed operations from start View Full Bio

Robert Discordia, Ph.D.

Vice President, Pharmaceutical Development & Manufacturing

Robert Discordia, Ph.D., joined Corbus as Vice President, Pharmaceutical Development & Manufacturing in May 2018. Dr. Discordia brings to Corbus more than 25 years of biopharmaceutical industry experience in CMC development and View Full Bio

Ross Lobell

Vice President, Regulatory Affairs

Ross Lobell joined Corbus as Vice President, Regulatory Affairs in April 2018. Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory View Full Bio

Alan Holmer

Chairman of the Board

Alan F. Holmer served from 1996 to 2005 as President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents the worldwide interests of leading pharmaceutical and View Full Bio

Avery W. Catlin

Director

Avery W. Catlin served (now retired) as Senior Vice President, Chief Financial Officer, and Secretary of Celldex Therapeutics, Inc., a public biopharmaceutical company. Prior to joining Celldex Therapeutics, Inc. in January 2000, he served View Full Bio

Yuval Cohen, Ph.D.

Chief Executive Officer, Director

David Hochman

Director

David Hochman is a Managing Partner of Orchestra Medical Ventures, an investment firm that employs an innovative strategy to create, build and invest in medical technology companies intended to generate substantial clinical value and View Full Bio

John Jenkins, M.D.

Director

Dr. Jenkins served as the Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, where he was responsible for more than 1,000 agency View Full Bio

Paris Panayiotopoulos

Director

Mr. Panayiotopoulos was most recently the President and Chief Executive Officer and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc., which was acquired by Takeda Pharmaceuticals for $5.2 billion in February 2017. Prior to View Full Bio

Corbus Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery

Latest News

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

Latest Financial Results

Q2 2018

Stock Information

Symbol

Price

Change

MKT Cap

Volume

Company Overview

Officers & Directors

Yuval Cohen, Ph.D.

Mark A. Tepper, Ph.D.

Barbara White, M.D.

Sean Moran, CPA, MBA

Robert Discordia, Ph.D.

Ross Lobell

Alan Holmer

Avery W. Catlin

Yuval Cohen, Ph.D.

David Hochman

John Jenkins, M.D.

Paris Panayiotopoulos

Corbus Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery

Overview

Latest News

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

Latest Financial Results

Q2 2018

Stock Information

Symbol

Price

Change

MKT Cap

Volume

Company Overview

Sign up for email alerts

Officers & Directors

Yuval Cohen, Ph.D.

Mark A. Tepper, Ph.D.

Barbara White, M.D.

Sean Moran, CPA, MBA

Robert Discordia, Ph.D.

Ross Lobell

Alan Holmer

Avery W. Catlin

Yuval Cohen, Ph.D.

David Hochman

John Jenkins, M.D.

Paris Panayiotopoulos